Health and Healthcare

Friday's Top Biotech and Medical Stocks

From Biohealth Investor

Biotechnology

NEURALSTEM INC [NRLS.OB] +9.09%
POLYDEX PHARM LTD [POLXF] +8.77%
MEMORY PHARMACEUTICA [MEMY] +7.32%
STEMCELLS INC [STEM] +6.75%
KOSAN BIOSCIENCES [KOSN] +5.78%

Diagnostic Substances

ICAGEN, INC. [ICGN] +22.81%
RG GLBL LIFESTYLS [RGBL.OB] +21.53%
BIOSITE INC [BSTE] +7.54%
GENE LOGIC INC [GLGC] +5.77%
AVIGEN INC [AVGN] +5.52%

Drug Delivery

IOMED INC [IOX] +3.45%
NOVADEL PHARMA INC [NVD] +3.42%
GENEREX BIOTECH CORP [GNBT] +3.11%
PENWEST PHARM CO [PPCO] +2.69%
BIOPROGRESS PLC [BPRG] +2.61%

Drug Manufacturers

ATHEROGENICS INC [AGIX] +24.07%
ENDO PHARM HLDGS I [ENDP] +5.40%
PROTALEX INC [PRTX.OB] +4.53%
AMARIN CORP PLC AD [AMRN] +4.13%
CHATTEM INC [CHTT] +4.10%

Medical Appliances & Equipment

HANSEN MEDICAL, INC. [HNSN] +8.91%
CHAD THERAPEUTICS [CTU] +5.72%
MICROTEK MED HLDGS [MTMD] +4.91%
UROLOGIX INC [ULGX] +3.97%
BSD MEDICAL CORP [BSM] +3.74%

Medical Instruments & Supplies

MILESTONE SCIENTIFIC [MLSS.OB] +16.92%
MEMRY CORPORATION [MRY] +9.09%
QUANTRX BIOMEDICAL [QTXB.OB] +7.20%
ATRICURE, INC. [ATRC] +6.13%
STEN CORPORATION [STEN] +5.63%

Medical Laboratories & Research

BIOFORCE NANOSCIENCE [BFNH.OB] +12.50%
AASTROM BIOSCIENCE [ASTM] +4.32%
BIO-IMAGING TECH [BITI] +3.60%
RADNET INC [RDNT.OB] +2.37%
MEDTOX SCIENTFIC INC [MTOX] +1.86%

http://biohealthinvestor.com/

Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)

If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.

Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.